126
|
Caroli M, Mele RM, Tomaselli MA, Cammisa M, Longo F, Attolini E. Complementary feeding patterns in Europe with a special focus on Italy. Nutr Metab Cardiovasc Dis 2012; 22:813-818. [PMID: 22898449 DOI: 10.1016/j.numecd.2012.07.007] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/08/2012] [Revised: 07/11/2012] [Accepted: 07/21/2012] [Indexed: 12/26/2022]
Abstract
Early nutrition is considered to be crucial for development of persistent obesity in later life. The aim of this paper is to present an overview of complementary feeding patterns across European countries. Most European infants introduce solid foods earlier than 6 completed months of age as recommended by WHO. The commonest risk factors for early introduction of solid foods have been shown to be smoking mothers of young age, low SES and no breastfeeding. The foods most frequently introduced as first solids are fruit and cereals followed by other foods that vary depending on the country of residence and the infants' type of feeding. Insufficient updated information has been made available in Europe in terms of infants' nutrient intake during complementary feeding, as well as on the potential acute metabolic effects of complementary feeding. Websites, e-forums and blogs on complementary feeding are widely spread in the web. The recipes and daily menus published in food industry websites are often nutritionally incorrect. Baby led-weaning (BLW) is based on the principle that babies, upon being started on complementary foods, should be allowed to eat whatever food they want (regular family foods included) in its normal shape. No nutrient intake and metabolic data are nevertheless available about BLW. The current scenario in terms of our understanding of complementary feeding in Europe opens several new research avenues. Not using and not improving our current knowledge of nutrition to improve children's health represents an infringement of children's rights.
Collapse
|
127
|
Grande E, Castellano D, García-Carbonero R, Teulé A, Durán I, Fuster J, Sevilla I, Escudero P, Sastre J, Casanovas O, Ortega L, Earl J, Díez J, de Velasco G, Longo F, Navarro A, Pachón V, Carrato A, Salazar R, Capdevila J. Pazonet: A Phase II Trial of Pazopanib as a Sequencing Treatment in Progressive Metastatic Neuroendocrine Tumors (NETS) Patients (PTS), On Behalf of The Spanish Task Force for Nets (GETNE). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33727-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
128
|
Longo F, Mansueto G, Lapadula V, Stumbo L, Del Bene G, Adua D, De Filippis L, Bonizzoni E, Quadrini S. Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy. Int J Clin Pract 2012; 66:753-757. [PMID: 22805267 PMCID: PMC3437500 DOI: 10.1111/j.1742-1241.2012.02969.x] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Introduction: With repeated courses of chemotherapy, chemotherapy-induced nausea and vomiting (CINV) becomes progressively more difficult to control. The aim of this study was to evaluate whether the antiemetic efficacy of the triple combination aprepitant, palonosetron and dexamethasone could be sustained for up to six cycles of highly emetogenic chemotherapy (HEC) (cisplatin ≥ 50 mg/m(2) ). Methods: Chemotherapy-naive patients receiving cisplatin-based HEC, were treated with palonosetron 0.25 mg/i.v., dexamethasone 20 mg/i.v. and aprepitant 125 mg/p.o. 1 h before chemotherapy. Aprepitant 80 mg/p.o. and dexamethasone 4 mg/p.o. were administered on days 2-3. The primary endpoint was complete response (CR, no vomiting and no use of rescue medication), over 5 days following HEC in up to six cycles. Secondary endpoints were emesis-free and nausea-free rates. Safety was also evaluated. Results: One hundred and fifty six lung cancer patients were included in the study; the median age was 64 years and 76.9% were men. The minimum cisplatin dosage was 75 mg/m(2) , and in most patients was combined with another drug (87.4%). CR ranged from 74.4% (first cycle) to 82% (sixth cycle). More than 90% and 60% of patients were emesis-free and nausea-free during all chemotherapy cycles. The most commonly reported side effects were constipation and headache. Conclusions: The triple combination of aprepitant, palonosetron and dexamethasone enhanced not only the antiemetic protection during the first cycle, but its efficacy was also sustained for up to six cycles of cisplatin-based HEC in lung cancer patients.
Collapse
|
129
|
Agbor G, Tarkang P, Fogha J, Biyiti L, Tamze V, Messi H, Tsabang N, Longo F, Tchinda A, Dongmo B, Donfagsite N, Mbing J, Joseph K, Ngide R, Simo D. Acute and Subacute Toxicity Studies of Aqueous Extract of Morinda lucida Stem Bark. ACTA ACUST UNITED AC 2012. [DOI: 10.3923/jpt.2012.158.165] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
130
|
Ackermann M, Ajello M, Allafort A, Atwood WB, Baldini L, Barbiellini G, Bastieri D, Bechtol K, Bellazzini R, Berenji B, Blandford RD, Bloom ED, Bonamente E, Borgland AW, Bouvier A, Bregeon J, Brigida M, Bruel P, Buehler R, Buson S, Caliandro GA, Cameron RA, Caraveo PA, Casandjian JM, Cecchi C, Charles E, Chekhtman A, Cheung CC, Chiang J, Ciprini S, Claus R, Cohen-Tanugi J, Conrad J, Cutini S, de Angelis A, de Palma F, Dermer CD, Digel SW, do Couto E Silva E, Drell PS, Drlica-Wagner A, Favuzzi C, Fegan SJ, Ferrara EC, Focke WB, Fortin P, Fukazawa Y, Funk S, Fusco P, Gargano F, Gasparrini D, Germani S, Giglietto N, Giommi P, Giordano F, Giroletti M, Glanzman T, Godfrey G, Grenier IA, Grove JE, Guiriec S, Gustafsson M, Hadasch D, Harding AK, Hayashida M, Hughes RE, Jóhannesson G, Johnson AS, Kamae T, Katagiri H, Kataoka J, Knödlseder J, Kuss M, Lande J, Latronico L, Lemoine-Goumard M, Llena Garde M, Longo F, Loparco F, Lovellette MN, Lubrano P, Madejski GM, Mazziotta MN, McEnery JE, Michelson PF, Mitthumsiri W, Mizuno T, Moiseev AA, Monte C, Monzani ME, Morselli A, Moskalenko IV, Murgia S, Nakamori T, Nolan PL, Norris JP, Nuss E, Ohno M, Ohsugi T, Okumura A, Omodei N, Orlando E, Ormes JF, Ozaki M, Paneque D, Parent D, Pesce-Rollins M, Pierbattista M, Piron F, Pivato G, Porter TA, Rainò S, Rando R, Razzano M, Razzaque S, Reimer A, Reimer O, Reposeur T, Ritz S, Romani RW, Roth M, Sadrozinski HFW, Sbarra C, Schalk TL, Sgrò C, Siskind EJ, Spandre G, Spinelli P, Strong AW, Takahashi H, Takahashi T, Tanaka T, Thayer JG, Thayer JB, Tibaldo L, Tinivella M, Torres DF, Tosti G, Troja E, Uchiyama Y, Usher TL, Vandenbroucke J, Vasileiou V, Vianello G, Vitale V, Waite AP, Winer BL, Wood KS, Wood M, Yang Z, Zimmer S. Measurement of separate cosmic-ray electron and positron spectra with the fermi large area telescope. PHYSICAL REVIEW LETTERS 2012; 108:011103. [PMID: 22304252 DOI: 10.1103/physrevlett.108.011103] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/02/2011] [Revised: 11/10/2011] [Indexed: 05/31/2023]
Abstract
We measured separate cosmic-ray electron and positron spectra with the Fermi Large Area Telescope. Because the instrument does not have an onboard magnet, we distinguish the two species by exploiting Earth's shadow, which is offset in opposite directions for opposite charges due to Earth's magnetic field. We estimate and subtract the cosmic-ray proton background using two different methods that produce consistent results. We report the electron-only spectrum, the positron-only spectrum, and the positron fraction between 20 and 200 GeV. We confirm that the fraction rises with energy in the 20-100 GeV range. The three new spectral points between 100 and 200 GeV are consistent with a fraction that is continuing to rise with energy.
Collapse
|
131
|
Ackermann M, Ajello M, Albert A, Atwood WB, Baldini L, Ballet J, Barbiellini G, Bastieri D, Bechtol K, Bellazzini R, Berenji B, Blandford RD, Bloom ED, Bonamente E, Borgland AW, Bregeon J, Brigida M, Bruel P, Buehler R, Burnett TH, Buson S, Caliandro GA, Cameron RA, Cañadas B, Caraveo PA, Casandjian JM, Cecchi C, Charles E, Chekhtman A, Chiang J, Ciprini S, Claus R, Cohen-Tanugi J, Conrad J, Cutini S, de Angelis A, de Palma F, Dermer CD, Digel SW, do Couto e Silva E, Drell PS, Drlica-Wagner A, Falletti L, Favuzzi C, Fegan SJ, Ferrara EC, Fukazawa Y, Funk S, Fusco P, Gargano F, Gasparrini D, Gehrels N, Germani S, Giglietto N, Giordano F, Giroletti M, Glanzman T, Godfrey G, Grenier IA, Guiriec S, Gustafsson M, Hadasch D, Hayashida M, Hays E, Hughes RE, Jeltema TE, Jóhannesson G, Johnson RP, Johnson AS, Kamae T, Katagiri H, Kataoka J, Knödlseder J, Kuss M, Lande J, Latronico L, Lionetto AM, Llena Garde M, Longo F, Loparco F, Lott B, Lovellette MN, Lubrano P, Madejski GM, Mazziotta MN, McEnery JE, Mehault J, Michelson PF, Mitthumsiri W, Mizuno T, Monte C, Monzani ME, Morselli A, Moskalenko IV, Murgia S, Naumann-Godo M, Norris JP, Nuss E, Ohsugi T, Okumura A, Omodei N, Orlando E, Ormes JF, Ozaki M, Paneque D, Parent D, Pesce-Rollins M, Pierbattista M, Piron F, Pivato G, Porter TA, Profumo S, Rainò S, Razzano M, Reimer A, Reimer O, Ritz S, Roth M, Sadrozinski HFW, Sbarra C, Scargle JD, Schalk TL, Sgrò C, Siskind EJ, Spandre G, Spinelli P, Strigari L, Suson DJ, Tajima H, Takahashi H, Tanaka T, Thayer JG, Thayer JB, Thompson DJ, Tibaldo L, Tinivella M, Torres DF, Troja E, Uchiyama Y, Vandenbroucke J, Vasileiou V, Vianello G, Vitale V, Waite AP, Wang P, Winer BL, Wood KS, Wood M, Yang Z, Zimmer S, Kaplinghat M, Martinez GD. Constraining dark matter models from a combined analysis of Milky Way satellites with the Fermi Large Area Telescope. PHYSICAL REVIEW LETTERS 2011; 107:241302. [PMID: 22242987 DOI: 10.1103/physrevlett.107.241302] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/18/2011] [Revised: 10/06/2011] [Indexed: 05/31/2023]
Abstract
Satellite galaxies of the Milky Way are among the most promising targets for dark matter searches in gamma rays. We present a search for dark matter consisting of weakly interacting massive particles, applying a joint likelihood analysis to 10 satellite galaxies with 24 months of data of the Fermi Large Area Telescope. No dark matter signal is detected. Including the uncertainty in the dark matter distribution, robust upper limits are placed on dark matter annihilation cross sections. The 95% confidence level upper limits range from about 10(-26) cm3 s(-1) at 5 GeV to about 5×10(-23) cm3 s(-1) at 1 TeV, depending on the dark matter annihilation final state. For the first time, using gamma rays, we are able to rule out models with the most generic cross section (∼3×10(-26) cm3 s(-1) for a purely s-wave cross section), without assuming additional boost factors.
Collapse
|
132
|
Fainardi V, Iacinti E, Longo F, Tripodi MC, Pisi G. P243 Anxiety and depression in adolescents and adults with cystic fibrosis. Thorax 2011. [DOI: 10.1136/thoraxjnl-2011-201054c.243] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
133
|
Freire PCC, Abdo AA, Ajello M, Allafort A, Ballet J, Barbiellini G, Bastieri D, Bechtol K, Bellazzini R, Blandford RD, Bloom ED, Bonamente E, Borgland AW, Brigida M, Bruel P, Buehler R, Buson S, Caliandro GA, Cameron RA, Camilo F, Caraveo PA, Cecchi C, Çelik Ö, Charles E, Chekhtman A, Cheung CC, Chiang J, Ciprini S, Claus R, Cognard I, Cohen-Tanugi J, Cominsky LR, de Palma F, Dermer CD, do Couto e Silva E, Dormody M, Drell PS, Dubois R, Dumora D, Espinoza CM, Favuzzi C, Fegan SJ, Ferrara EC, Focke WB, Fortin P, Fukazawa Y, Fusco P, Gargano F, Gasparrini D, Gehrels N, Germani S, Giglietto N, Giordano F, Giroletti M, Glanzman T, Godfrey G, Grenier IA, Grondin MH, Grove JE, Guillemot L, Guiriec S, Hadasch D, Harding AK, Jóhannesson G, Johnson AS, Johnson TJ, Johnston S, Katagiri H, Kataoka J, Keith M, Kerr M, Knödlseder J, Kramer M, Kuss M, Lande J, Latronico L, Lee SH, Lemoine-Goumard M, Longo F, Loparco F, Lovellette MN, Lubrano P, Lyne AG, Manchester RN, Marelli M, Mazziotta MN, McEnery JE, Michelson PF, Mizuno T, Moiseev AA, Monte C, Monzani ME, Morselli A, Moskalenko IV, Murgia S, Nakamori T, Nolan PL, Norris JP, Nuss E, Ohsugi T, Okumura A, Omodei N, Orlando E, Ozaki M, Paneque D, Parent D, Pesce-Rollins M, Pierbattista M, Piron F, Porter TA, Rainò S, Ransom SM, Ray PS, Reimer A, Reimer O, Reposeur T, Ritz S, Romani RW, Roth M, Sadrozinski HFW, Parkinson PMS, Sgrò C, Shannon R, Siskind EJ, Smith DA, Smith PD, Spinelli P, Stappers BW, Suson DJ, Takahashi H, Tanaka T, Tauris TM, Thayer JB, Theureau G, Thompson DJ, Thorsett SE, Tibaldo L, Torres DF, Tosti G, Troja E, Vandenbroucke J, Van Etten A, Vasileiou V, Venter C, Vianello G, Vilchez N, Vitale V, Waite AP, Wang P, Wood KS, Yang Z, Ziegler M, Zimmer S. Fermi Detection of a Luminous γ-Ray Pulsar in a Globular Cluster. Science 2011; 334:1107-10. [PMID: 22052973 DOI: 10.1126/science.1207141] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
134
|
Ackermann M, Ajello M, Allafort A, Baldini L, Ballet J, Barbiellini G, Bastieri D, Belfiore A, Bellazzini R, Berenji B, Blandford RD, Bloom ED, Bonamente E, Borgland AW, Bottacini E, Brigida M, Bruel P, Buehler R, Buson S, Caliandro GA, Cameron RA, Caraveo PA, Casandjian JM, Cecchi C, Chekhtman A, Cheung CC, Chiang J, Ciprini S, Claus R, Cohen-Tanugi J, de Angelis A, de Palma F, Dermer CD, do Couto e Silva E, Drell PS, Dumora D, Favuzzi C, Fegan SJ, Focke WB, Fortin P, Fukazawa Y, Fusco P, Gargano F, Germani S, Giglietto N, Giordano F, Giroletti M, Glanzman T, Godfrey G, Grenier IA, Guillemot L, Guiriec S, Hadasch D, Hanabata Y, Harding AK, Hayashida M, Hayashi K, Hays E, Johannesson G, Johnson AS, Kamae T, Katagiri H, Kataoka J, Kerr M, Knodlseder J, Kuss M, Lande J, Latronico L, Lee SH, Longo F, Loparco F, Lott B, Lovellette MN, Lubrano P, Martin P, Mazziotta MN, McEnery JE, Mehault J, Michelson PF, Mitthumsiri W, Mizuno T, Monte C, Monzani ME, Morselli A, Moskalenko IV, Murgia S, Naumann-Godo M, Nolan PL, Norris JP, Nuss E, Ohsugi T, Okumura A, Orlando E, Ormes JF, Ozaki M, Paneque D, Parent D, Pesce-Rollins M, Pierbattista M, Piron F, Pohl M, Prokhorov D, Raino S, Rando R, Razzano M, Reposeur T, Ritz S, Parkinson PMS, Sgro C, Siskind EJ, Smith PD, Spinelli P, Strong AW, Takahashi H, Tanaka T, Thayer JG, Thayer JB, Thompson DJ, Tibaldo L, Torres DF, Tosti G, Tramacere A, Troja E, Uchiyama Y, Vandenbroucke J, Vasileiou V, Vianello G, Vitale V, Waite AP, Wang P, Winer BL, Wood KS, Yang Z, Zimmer S, Bontemps S. A Cocoon of Freshly Accelerated Cosmic Rays Detected by Fermi in the Cygnus Superbubble. Science 2011; 334:1103-7. [DOI: 10.1126/science.1210311] [Citation(s) in RCA: 180] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
135
|
Marabese M, Rulli E, Bettini A, Farina G, Longo F, Moscetti L, Pavese I, Lauricella C, Broggini M, Garassino M. 1143 POSTER KRAS Mutational Status Strongly Impact Progression Free Survival of Patients Treated With Platinum Based Chemotherapy in NSCLC -Final Results of a Multicenter Prospective Study. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)70786-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
136
|
Mansueto G, Longo F, Stumbo L, De Filippis L, Del Signore E, Quadrini S, Del Bene G, Adua D, Lapadula V, Di Seri M. 4023 POSTER First-line Oral Vinorelbine for Elderly or Unfit Patients With Advanced/metastatic Non-small Cell Lung Cancer. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71266-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
137
|
Ajello M, Atwood WB, Baldini L, Barbiellini G, Bastieri D, Bellazzini R, Berenji B, Blandford RD, Bloom ED, Bonamente E, Borgland AW, Bottacini E, Bouvier A, Bregeon J, Brigida M, Bruel P, Buehler R, Buson S, Caliandro GA, Cameron RA, Caraveo PA, Cecchi C, Charles E, Chekhtman A, Ciprini S, Claus R, Cohen-Tanugi J, Cutini S, de Angelis A, de Palma F, Dermer CD, Digel SW, do Couto e Silva E, Drell PS, Favuzzi C, Fegan SJ, Focke WB, Fukazawa Y, Fusco P, Gargano F, Gehrels N, Germani S, Giglietto N, Giordano F, Giroletti M, Glanzman T, Godfrey G, Grenier IA, Guiriec S, Gustafsson M, Hadasch D, Iafrate G, Jóhannesson G, Johnson AS, Kamae T, Katagiri H, Kataoka J, Kuss M, Latronico L, Lionetto AM, Longo F, Loparco F, Lovellette MN, Lubrano P, Mazziotta MN, McEnery JE, Michelson PF, Mizuno T, Monte C, Monzani ME, Morselli A, Moskalenko IV, Murgia S, Naumann-Godo M, Norris JP, Nuss E, Ohsugi T, Omodei N, Orlando E, Ormes JF, Ozaki M, Paneque D, Panetta JH, Pesce-Rollins M, Pierbattista M, Piron F, Rainò S, Rando R, Razzano M, Reimer A, Reimer O, Ritz S, Schalk TL, Sgrò C, Siegal-Gaskins J, Siskind EJ, Smith PD, Spandre G, Spinelli P, Suson DJ, Takahashi H, Tanaka T, Thayer JG, Thayer JB, Tibaldo L, Tosti G, Troja E, Usher TL, Vandenbroucke J, Vasileiou V, Vianello G, Vilchez N, Waite AP, Wang P, Winer BL, Wood KS, Yang Z, Zimmer S. Constraints on dark matter models from a Fermi LAT search for high-energy cosmic-ray electrons from the Sun. Int J Clin Exp Med 2011. [DOI: 10.1103/physrevd.84.032007] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
138
|
Gazzaniga P, Raimondi C, Gradilone A, Di Seri M, Longo F, Cortesi E, Frati L. Circulating tumor cells, colon cancer and bevacizumab: the meaning of zero. Ann Oncol 2011; 22:1929-30. [PMID: 21633048 DOI: 10.1093/annonc/mdr292] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
139
|
Rossi L, Veltri E, Colonna M, Zoratto F, Vari S, Mottolese M, Di Seri M, Romiti A, Longo F, Giannarelli D, Tomao S. Biomolecular, biochemical, and radiologic evaluation and safety of chemotherapy with bevacizumab in treatment of patients affected by mCRC. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e14140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
140
|
Vaccaro A, Ciancola F, Pizzuti L, Sperduti I, Moscetti L, Vici P, Longo F, Ruggeri E, Di Seri M, Giampaolo MA, Gamucci T. High recurrence risk in pT1bc HER2-positive, triple-negative, node-negative early breast cancer patients. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
141
|
Mangone G, Longo F, Friscia M, Ferrara S, Califano L. Morbidity of teeth in the line of the fracture. MINERVA STOMATOLOGICA 2011; 60:223-227. [PMID: 21597427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
AIM Management of a jaw fracture in which a tooth lies in the fracture line is controversial. In the past, teeth were generally removed because they were thought to be the cause of infections or locus minoris resistentiae. To provide a better indication in the management of teeth in the fracture line and the relate complications we retrospectively reviewed the files particularly in relation to treatment options. METHODS From 1999 to 2009 a total of 478 patients with jaw fracture were observed at the Maxillofacial Department of the University "Federico II" of Naples. RESULTS In 63 cases the fracture involved the angle of the mandible and in 48 a tooth lay in the fracture line. Of the 48 teeth in the fracture line, 14 were removed for various causes. Surgical treatment consisted of fracture reduction and fixation by titanium plates and screws. CONCLUSION We suggest few guiding lines in the management of teeth in fracture lines that need to be extracted only in particular conditions. Finally there are few cases of later dental complications that can affect the teeth in the fracture line after the osseous healing process of the fractures. These cases require a follow-up of three-six months, and the treatment is the same commonly described in Literature for dental trauma.
Collapse
|
142
|
Barone G, Crupi V, Longo F, Majolino D, Mazzoleni P, Tanasi D, Venuti V. FT-IR spectroscopic analysis to study the firing processes of prehistoric ceramics. J Mol Struct 2011. [DOI: 10.1016/j.molstruc.2010.12.018] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
143
|
Barone G, Crupi V, Longo F, Majolino D, Mazzoleni P, Venuti V. Characterisation of archaeological pottery: The case of “Ionian Cups”. J Mol Struct 2011. [DOI: 10.1016/j.molstruc.2011.01.028] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
144
|
Tavani M, Bulgarelli A, Vittorini V, Pellizzoni A, Striani E, Caraveo P, Weisskopf MC, Tennant A, Pucella G, Trois A, Costa E, Evangelista Y, Pittori C, Verrecchia F, Del Monte E, Campana R, Pilia M, De Luca A, Donnarumma I, Horns D, Ferrigno C, Heinke CO, Trifoglio M, Gianotti F, Vercellone S, Argan A, Barbiellini G, Cattaneo PW, Chen AW, Contessi T, D’Ammando F, DeParis G, Di Cocco G, Di Persio G, Feroci M, Ferrari A, Galli M, Giuliani A, Giusti M, Labanti C, Lapshov I, Lazzarotto F, Lipari P, Longo F, Fuschino F, Marisaldi M, Mereghetti S, Morelli E, Moretti E, Morselli A, Pacciani L, Perotti F, Piano G, Picozza P, Prest M, Rapisarda M, Rappoldi A, Rubini A, Sabatini S, Soffitta P, Vallazza E, Zambra A, Zanello D, Lucarelli F, Santolamazza P, Giommi P, Salotti L, Bignami GF. Discovery of Powerful Gamma-Ray Flares from the Crab Nebula. Science 2011; 331:736-9. [DOI: 10.1126/science.1200083] [Citation(s) in RCA: 249] [Impact Index Per Article: 19.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
145
|
Abdo AA, Ackermann M, Ajello M, Allafort A, Baldini L, Ballet J, Barbiellini G, Bastieri D, Bechtol K, Bellazzini R, Berenji B, Blandford RD, Bloom ED, Bonamente E, Borgland AW, Bouvier A, Brandt TJ, Bregeon J, Brez A, Brigida M, Bruel P, Buehler R, Buson S, Caliandro GA, Cameron RA, Cannon A, Caraveo PA, Casandjian JM, Çelik Ö, Charles E, Chekhtman A, Cheung CC, Chiang J, Ciprini S, Claus R, Cohen-Tanugi J, Costamante L, Cutini S, D’Ammando F, Dermer CD, de Angelis A, de Luca A, de Palma F, Digel SW, do Couto e Silva E, Drell PS, Drlica-Wagner A, Dubois R, Dumora D, Favuzzi C, Fegan SJ, Ferrara EC, Focke WB, Fortin P, Frailis M, Fukazawa Y, Funk S, Fusco P, Gargano F, Gasparrini D, Gehrels N, Germani S, Giglietto N, Giordano F, Giroletti M, Glanzman T, Godfrey G, Grenier IA, Grondin MH, Grove JE, Guiriec S, Hadasch D, Hanabata Y, Harding AK, Hayashi K, Hayashida M, Hays E, Horan D, Itoh R, Jóhannesson G, Johnson AS, Johnson TJ, Khangulyan D, Kamae T, Katagiri H, Kataoka J, Kerr M, Knödlseder J, Kuss M, Lande J, Latronico L, Lee SH, Lemoine-Goumard M, Longo F, Loparco F, Lubrano P, Madejski GM, Makeev A, Marelli M, Mazziotta MN, McEnery JE, Michelson PF, Mitthumsiri W, Mizuno T, Moiseev AA, Monte C, Monzani ME, Morselli A, Moskalenko IV, Murgia S, Nakamori T, Naumann-Godo M, Nolan PL, Norris JP, Nuss E, Ohsugi T, Okumura A, Omodei N, Ormes JF, Ozaki M, Paneque D, Parent D, Pelassa V, Pepe M, Pesce-Rollins M, Pierbattista M, Piron F, Porter TA, Rainò S, Rando R, Ray PS, Razzano M, Reimer A, Reimer O, Reposeur T, Ritz S, Romani RW, Sadrozinski HFW, Sanchez D, Parkinson PMS, Scargle JD, Schalk TL, Sgrò C, Siskind EJ, Smith PD, Spandre G, Spinelli P, Strickman MS, Suson DJ, Takahashi H, Takahashi T, Tanaka T, Thayer JB, Thompson DJ, Tibaldo L, Torres DF, Tosti G, Tramacere A, Troja E, Uchiyama Y, Vandenbroucke J, Vasileiou V, Vianello G, Vitale V, Wang P, Wood KS, Yang Z, Ziegler M. Gamma-Ray Flares from the Crab Nebula. Science 2011; 331:739-42. [DOI: 10.1126/science.1199705] [Citation(s) in RCA: 265] [Impact Index Per Article: 20.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
146
|
Rossi L, Veltri E, Di Seri M, Vari S, Colonna M, Adua D, Longo F, Zoratto F, Mottolese M, Tomao S. Biomolecular, biochemical, and radiologic evaluation of patients on anti-VEGF treatment for mCRC. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
556 Background: K-ras mutation is a negative predictor of clinical benefit (CB) from anti-EGFR treatment in mCRC. Bevacizumab combined with chemotherapy prolongs both PFS and OS in first-line treatment of mCRC. Previously data suggested that this results are independent of K-ras status. We conducted a study to investigate the CB of Bevacizumab in treatment of mCRC according to K-ras status and to evaluate timing of response to treatment trough the correlation between tumor markers values and clinical responses. Finally we evaluated CB in patients affected by mCRC with only hepatic metastases vs patients with multiple metastasis sites. Methods: 82 patients were enrolled and underwent first-line chemotherapy with Folfiri or FolFoX and bevacizumab. Tissue samples were analyzed for DNA sequencing in order to identify K-ras mutations in codons 12 and 13. Before therapy all patients were investigated with CT scan and with a blood sample to define tumor markers values; a new evaluation of tumor markers after 2 months of chemotherapy was performed and a CT scan after 3 months. Results: An overall objective response rate (RR) of 40% and a CB of 79% were obtained, with a correlation between tumor markers values and clinical response of 89%. 49% of population presented only hepatic metastases while other 51% showed multiple metastatic sites. RR in exclusive hepatic metastatic group was 45% vs 33% multiple metastatic sites group, CB was 90% vs 66% respectively. No grade 3 or 4 bevacizumab associated toxicity was showed in patients. K-ras mutations were investigated in 75 of 82 patients. 49 patients were wild-type (wt 65%) while 26 patients were mutated (mut 35%). RR in wt group was 45% vs 35% in mut group, while CB was 82% vs 81% respectively. Correlation between tumor markers values and clinical response was 90% in wt group vs 93% in mut group. Conclusions: RR in two K-ras groups was different with an advantage in K-ras wt group, but this difference does not observe in CB. Bevacizumab provides significant RR and CB after a short time of treatment and tumor markers values could be an optimal correlative parameters of early clinical response. Bevacizumab provides significant CB in patients with only hepatic metastases vs patients with multiple metastatic sites. No significant financial relationships to disclose.
Collapse
|
147
|
Tavani M, Marisaldi M, Labanti C, Fuschino F, Argan A, Trois A, Giommi P, Colafrancesco S, Pittori C, Palma F, Trifoglio M, Gianotti F, Bulgarelli A, Vittorini V, Verrecchia F, Salotti L, Barbiellini G, Caraveo P, Cattaneo PW, Chen A, Contessi T, Costa E, D'Ammando F, Del Monte E, De Paris G, Di Cocco G, Di Persio G, Donnarumma I, Evangelista Y, Feroci M, Ferrari A, Galli M, Giuliani A, Giusti M, Lapshov I, Lazzarotto F, Lipari P, Longo F, Mereghetti S, Morelli E, Moretti E, Morselli A, Pacciani L, Pellizzoni A, Perotti F, Piano G, Picozza P, Pilia M, Pucella G, Prest M, Rapisarda M, Rappoldi A, Rossi E, Rubini A, Sabatini S, Scalise E, Soffitta P, Striani E, Vallazza E, Vercellone S, Zambra A, Zanello D. Terrestrial gamma-ray flashes as powerful particle accelerators. PHYSICAL REVIEW LETTERS 2011; 106:018501. [PMID: 21231775 DOI: 10.1103/physrevlett.106.018501] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/16/2010] [Indexed: 05/30/2023]
Abstract
Strong electric discharges associated with thunderstorms can produce terrestrial gamma-ray flashes (TGFs), i.e., intense bursts of x rays and γ rays lasting a few milliseconds or less. We present in this Letter new TGF timing and spectral data based on the observations of the Italian Space Agency AGILE satellite. We determine that the TGF emission above 10 MeV has a significant power-law spectral component reaching energies up to 100 MeV. These results challenge TGF theoretical models based on runaway electron acceleration. The TGF discharge electric field accelerates particles over the large distances for which maximal voltages of hundreds of megavolts can be established. The combination of huge potentials and large electric fields in TGFs can efficiently accelerate particles in large numbers, and we reconsider here the photon spectrum and the neutron production by photonuclear reactions in the atmosphere.
Collapse
|
148
|
Pannone G, Bufo P, Santoro A, Franco R, Aquino G, Longo F, Botti G, Serpico R, Cafarelli B, Abbruzzese A, Caraglia M, Papagerakis S, Lo Muzio L. WNT pathway in oral cancer: epigenetic inactivation of WNT-inhibitors. Oncol Rep 2011; 24:1035-41. [PMID: 20811686 DOI: 10.3892/or.2010.1035] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Epigenetic DNA methylations plays an important role in oral carcinogenesis. The soluble frizzled receptor protein (SFRP) family together with WIF-1 and DKK-3 encodes antagonists of the WNT pathway. Silencing of these genes leads to constitutive WNT signalling. Because aberrant expression of beta-catenin might be associated with the epigenetic inactivation of WNT inhibitors, we analyzed, in a collection of primary OSCC with matched normal oral mucosa, the methylation status of a complete panel of genes, SFRP-1, SFRP-2, SFRP-4, SFRP-5, WIF-1, DKK-3, that are involved directly and indirectly in WNT pathway, in order to demonstrate WNT-pathway activation in the absence of beta-catenin and/or APC/Axin mutations during oral carcinogenesis. Methylation-specific PCR (MSP) was performed to study inactivation of SFRP-1, SFRP-2, SFRP-4, SFRP-5, WIF-1, DKK-3 genes in 37 cases of paraffin embedded oral cancer. This study showed that the methylation is an important epigenetic alteration in oral cancer. In particular, SFRP-2, SFRP-4, SFRP-5, WIF-1, DKK-3 revealed methylation status of their promoter in OSCC, whereas SFRP-1 showed demethylation in cancer. Fisher's exact test revealed statistically significant results (p<0.05) for all genes. The Wald test confirmed the statistically significant association between SFRP2-4-5 gene methylation and OSCC (p<0.05). SFRP-1 was also characterized by a different statistically significant epigenetic behaviour, because of it was demethylated in cancer (p<0.05). Statistical regression test showed high levels of sensitivity, specificity and accuracy for SFRP genes, while WIF-1 and DKK-3 have reportedly high specificity, moderate accuracy but low sensitivity. This study suggests that a cause of catenin delocalization in oral cancer could be due to WNT pathway activation, by epigenetic alterations of SFRP, WIF-1 and DKK-3 genes.
Collapse
|
149
|
Cantisani V, Ricci P, Erturk M, Pagliara E, Drudi F, Calliada F, Mortele K, D'Ambrosio U, Marigliano C, Catalano C, Marin D, Di Seri M, Longo F, Passariello R. Detection of hepatic metastases from colorectal cancer: prospective evaluation of gray scale US versus SonoVue® low mechanical index real time-enhanced US as compared with multidetector-CT or Gd-BOPTA-MRI. ULTRASCHALL IN DER MEDIZIN (STUTTGART, GERMANY : 1980) 2010; 31:500-505. [PMID: 20408122 DOI: 10.1055/s-0028-1109751] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
PURPOSE To compare ultrasound (US), low-mechanical index contrast enhanced US (CEUS) and multidetector-CT (MDCT) for the detection of hepatic metastases from colorectal cancer. METHODS AND MATERIALS From January to June 2006, 110 patients (65 males, 45 females; mean age 62 years; range 39-78) with suspected hepatic lesions from colorectal cancer were prospectively evaluated with US, CEUS and MDCT by two independent readers. Intraoperative ultrasonography (IOUS, n = 45) or a follow-up up for at least 6 months by using MDCT or Gd-BOPTA-enhanced MRI was considered the gold standard. McNemar test was employed. RESULTS Reference standards revealed 430 metastases in 110 patients. On a patient-by-patients analysis, CEUS improved US sensitivity from 67.4-71.6% to 93.4-95.8% (p < 0.05). On a lesion-by-lesion analysis, CEUS improved the sensitivity of US from 60.9-64.9% to 85.3-92.8% (p < 0.001). The specificity increased from 50-60% to 76.7-83.3%. No significant differences in sensitivity or specificity between CEUS and MDCT were found. Contrast-enhanced US was significantly more sensitive than baseline US in the detection of metastases smaller than 1 cm (p < 0.001) with an increase in sensitivity from 29.1-35% to 63.3-76.6% no significant statistical difference was identified when compared with MDCT (sensitivity of 73.3-75.8%). CONCLUSIONS CEUS is significantly more accurate than US and highly comparable with MDCT in the detection of liver metastases from colorectal cancer. Therefore, in the evaluation of patients with suspected hepatic metastases from colorectal tumour, US examination must be performed after contrast administration.
Collapse
|
150
|
Marisaldi M, Argan A, Trois A, Giuliani A, Tavani M, Labanti C, Fuschino F, Bulgarelli A, Longo F, Barbiellini G, Del Monte E, Moretti E, Trifoglio M, Costa E, Caraveo P, Cattaneo PW, Chen A, D'Ammando F, De Paris G, Di Cocco G, Di Persio G, Donnarumma I, Evangelista Y, Feroci M, Ferrari A, Fiorini M, Froysland T, Galli M, Gianotti F, Lapshov I, Lazzarotto F, Lipari P, Mereghetti S, Morselli A, Pacciani L, Pellizzoni A, Perotti F, Picozza P, Piano G, Pilia M, Prest M, Pucella G, Rapisarda M, Rappoldi A, Rubini A, Sabatini S, Soffitta P, Striani E, Vallazza E, Vercellone S, Vittorini V, Zambra A, Zanello D, Antonelli LA, Colafrancesco S, Cutini S, Giommi P, Lucarelli F, Pittori C, Santolamazza P, Verrecchia F, Salotti L. Gamma-ray localization of terrestrial gamma-ray flashes. PHYSICAL REVIEW LETTERS 2010; 105:128501. [PMID: 20867680 DOI: 10.1103/physrevlett.105.128501] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/24/2010] [Indexed: 05/29/2023]
Abstract
Terrestrial gamma-ray flashes (TGFs) are very short bursts of high-energy photons and electrons originating in Earth's atmosphere. We present here a localization study of TGFs carried out at gamma-ray energies above 20 MeV based on an innovative event selection method. We use the AGILE satellite Silicon Tracker data that for the first time have been correlated with TGFs detected by the AGILE Mini-Calorimeter. We detect 8 TGFs with gamma-ray photons of energies above 20 MeV localized by the AGILE gamma-ray imager with an accuracy of ∼5-10° at 50 MeV. Remarkably, all TGF-associated gamma rays are compatible with a terrestrial production site closer to the subsatellite point than 400 km. Considering that our gamma rays reach the AGILE satellite at 540 km altitude with limited scattering or attenuation, our measurements provide the first precise direct localization of TGFs from space.
Collapse
|